Navigation Links
Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient

ST. LOUIS, July 16 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that the pediatric cardiology team at the Heart and Diabetes Center of North Reinland-Westphalia in Bad Oeynhausen, Germany, successfully performed a first-of-its-kind-procedure to treat pulmonary atresia in a 10-year old boy. The team performed the procedure with Stereotaxis' Niobe Magnetic Navigation System.

Pulmonary atresia is a congenital malformation of the pulmonary valve which obstructs the flow of blood from the heart to the lungs. As a result, blood is forced to flow to the lungs through a hole in the inner wall of the heart, known as a ventricular septal defect, and around a circuitous route through small, winding vessels. The disease severely limits the efficient transport of oxygen throughout the body.

This patient had failed a previous surgical attempt to correct the atresia because there were no vessels of adequate size or quality to utilize. After two conventional catheterization attempts, the Bad Oeynhausen team, lead by Dr. Nikolaus Haas, Director of the Catheterization Laboratory in the Department of Congenital Heart Defects at the Heart and Diabetes Center, used Stereotaxis' software to create a 3D model of the tortuous vessels that had replaced this patient's absent pulmonary artery. The Niobe Magnetic Navigation System then made it possible for the team to navigate a magnetic guidewire through the entire length of the difficult vessel and place a specialized stent that now permits increased blood flow from the aorta to the left lung, increasing the amount of oxygen that can be pumped around the body.

Fewer than 2 days after the procedure, the young patient was discharged from the hospital. Before the procedure, the patient was cyanotic, appearing blue due to insufficient oxygen supply, and could not walk 100 meters without running out of breath. Today, his color is good, and he is able to walk more than 1000 meters before needing to rest. Dr. Hass believes that the patient will experience still greater improvement after a second, planned procedure to improve blood flow to his right lung, and that the patient is well on the road to being able to participate in day-to-day activities, like walking to school and playing with friends.

"With the Stereotaxis technology, we are now able to help patients whose quality of life is extremely limited by severe congenital heart defects that have few viable treatment options," said Dr. Haas. "This patient nearly died during an earlier conventional procedure, and we thought we had exhausted our options to improve his quality of life. Based on this initial experience with the Stereotaxis System, we have already scheduled another patient with pulmonary atresia for this new procedure. In our current patient population alone there are at least 20 additional children with this disease who can benefit from the unique capabilities of the Stereotaxis technology."

"We are extremely gratified to see this young boy's life change so dramatically, and we applaud the ingenuity of Dr. Haas and his team," said Bevil Hogg, CEO of Stereotaxis. "This case underscores the value of the Niobe Navigation System as a platform for a broad range of interventional procedures beyond our core electrophysiology applications, and it is very rewarding to be part of such a groundbreaking application of our technology."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
2. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
3. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
4. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
5. Stereotaxis Receives $20 Million in Additional Loan Commitments
6. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
7. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
8. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
9. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
10. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. Stereotaxis Reports Record First Quarter Orders
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... RoamRight, a leading ... with Public Television’s Travel With Kids to promote family vacations around ... family as they explore international destinations and educate families about the people and places ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare Orthopedic ... orthopedic care. Led by John Vitolo, M.D., the center offers their patients ... team at Advocare Orthopedic & Sports Medicine is ready to help their patients ...
(Date:11/30/2015)... ... November 30, 2015 , ... International telepathology consultations ... and KingMed Diagnostics researchers. Their review of more than 1,500 ... UPMC pathologists resulted in significantly altered treatment plans for more than half of ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical Pathology (ASCP) announced ... Day 2015. On Nov. 30, ASCP shared its “Give a minute. Get tested. Find ... and the importance of getting tested for HIV. , ASCP has asked members to ...
(Date:11/30/2015)... ... ... An inventor from Charlottesville, Va., is concerned about the need for peace and ... due to loud noises," she said, "so I decided that there needs to be ... radio waves and microwaves." , The baby BABY MUFF prevents loud noises, radio waves ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Texas , Nov. 30, 2015  Hanger, Inc. ... amendment and restatement of the terms of its previously ... Solicitation") relating to its $200,000,000 aggregate principal amount 7⅛% ... other things, (i) the consent fees payable pursuant to ... on the Notes and (iii) the expiration date of ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
Breaking Medicine Technology: